Changeflow GovPing Pharma & Healthcare Fecal Microbiome Signature of Multi-Strain Prob...
Routine Notice Added Final

Fecal Microbiome Signature of Multi-Strain Probiotics Supplementation in Pediatric IBD

Favicon for changeflow.com ClinicalTrials.gov Studies
Published
Detected
Email

Summary

The NIH has registered a clinical trial (NCT07533890) to study fecal microbiome and metabolic profiles in children and adolescents with inflammatory bowel disease upon multi-strain probiotic supplementation. The study will enroll participants and begin interventions on April 16, 2026.

Published by NIH on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The NIH has registered a new clinical trial on ClinicalTrials.gov to investigate the effects of multi-strain probiotic supplementation on intestinal microbiome and metabolic profiles in pediatric patients with inflammatory bowel disease. The study will use probiotic formula as an active intervention compared to observation in children and adolescents.

Healthcare providers and clinical investigators should note this upcoming trial for awareness of emerging probiotic research in pediatric gastroenterology. Patients and families seeking enrollment in IBD microbiome studies may benefit from monitoring ClinicalTrials.gov for updated enrollment information as the April 2026 start date approaches.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 16, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

Fecal Microbiome Signature of Multi-Strain Probiotics Supplementation in Children and Adolescents With Inflammatory Bowel Disease

N/A NCT07533890 Kind: NA Apr 16, 2026

Abstract

In this study the intestinal microbiome and metabolic profiles of patients with inflammatory bowel disease will be determined upon probiotic intervention.

Conditions: Inflamatory Bowel Disease

Interventions: Probiotic Formula, Observation

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Published
April 16th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
NCT07533890

Who this affects

Applies to
Healthcare providers Clinical investigators Patients
Industry sector
3254.1 Biotechnology 6211 Healthcare Providers
Activity scope
Clinical trial registry Microbiome research Pediatric IBD studies
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Clinical Operations
Topics
Pharmaceuticals Public Health

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!